Close Menu

More articles about Drug Discovery & Development

Broad and One Mind scientists will use single-cell RNA sequencing technologies to investigate the role of microglia in Alzheimer's disease onset and progression.

Caris will use its suite of technologies to help Elevation Oncology enroll patients with NRG1 fusion-positive solid tumors to its Phase II trial of seribantumab.

Avatamed will use the funds to expand into the Asia-Pacific market and set up a lab in Singapore to provide precision cancer drug screening services.

GeneCentric and Erasmus will aim to identify RNA-based drug response markers for existing bladder cancer treatments, as well as discover novel targeted therapies.

Metabolon's Precision Metabolomics platform identifies pharmacodynamic, efficacy, and response biomarkers and tracks changes in biological pathways.

The firms will combine real-life data sets in rare diseases with expertise in big data, artificial intelligence, and computational algorithms.

The acquisition will give Curi access to Dana's portfolio of artificial intelligence and machine learning technologies for in vitro cell-based assays.

The companies hope to combine their technologies to provide pharmaceutical customers with an end-to-end workflow for multiplex histological staining and imaging. 

The partners will use ReviveMed's AI-driven platform to better understand mechanisms of immunotherapy response and resistance in cancer patients.

Caris will sequence DNA and RNA for certain cancer patients and potentially help Merus enroll cancer patients with NRG1 fusions in the Phase I/II eNRGy trial for zenocutuzumab.

Twist will give Takeda access to its phage display libraries to help Takeda discover and validate antibodies needed for the development of new biologics. 

The company will apply its single-cell RNA-seq analytics technology to three distinct cohorts in pursuit of new drug targets for inflammatory bowel disease. 

The company said it will use the funds in part to continue development of its artificial intelligence-based proteome-wide drug discovery platform.

The latest group includes several firm developing genomics tools or diagnostics, but COVID-19 is preventing them from accessing their lab space for the time being.

The accelerated approval is based on results from two cohorts of a Phase II, single-arm trial in which EZH2-mutated patients had an overall response rate of 69 percent.

The firm's technology uses ex vivo organ culture to model cancer growth and predict a patient's tumor response to chemotherapy and targeted drugs. 

The firms are targeting a compatible offering for single-cell gene expression screens following CRISPR-based editing, with applications in drug discovery.

These hybrid capture-based methods target gene transcripts of interest, which could shrink sequencing costs for some experiments by as much as 90 percent.

Single-cell analysis, next-generation sequencing, and synthetic DNA have all been crucial to efforts to find antibodies that could neutralize SARS-CoV-2.

Silicon Valley venture capital firm Andreessen Horowitz led the round, joined by 8VC, SV Angel, Allen & Co, and several other undisclosed private investors.

Pages

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.